{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:03:58Z","timestamp":1777417438952,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Complement system dysregulation, such as complement Factor H (CFH) autoantibodies and deletions in CFH-related (<jats:italic toggle=\"yes\">CFHR<\/jats:italic>) genes 3 and 1, might cause transplant-associated thrombotic microangiopathy (TA-TMA). The use of eculizumab, a terminal complement inhibitor, could be a targeted therapy for TA-TMA. We report a 1-year-old girl who developed TA-TMA, just after autologous peripheral blood stem cell transplantation in neuroblastoma therapy. Eculizumab improved TA-TMA. Investigation for the complement alternative pathway showed a heterozygous <jats:italic toggle=\"yes\">CFHR3<\/jats:italic>-<jats:italic toggle=\"yes\">CFHR1<\/jats:italic> gene deletion, which is involved in complement activation. The patient might develop TA-TMA as a result of complement regulatory gene mutation.<\/jats:p>","DOI":"10.1097\/mph.0000000000000986","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T16:17:30Z","timestamp":1507133850000},"page":"e544-e546","source":"Crossref","is-referenced-by-count":9,"title":["A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab"],"prefix":"10.1097","volume":"40","author":[{"given":"Akifumi","family":"Nozawa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"Pediatrics and Cell Transplantation, Mie University Graduate School of Medicine, Tsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Fukao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1053\/j.ajkd.2012.07.028","article-title":"Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab","volume":"61","author":"Schmidtko","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"R5-20230918","first-page":"4040","article-title":"Marginal benefit\/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT","volume":"92","author":"Kawano","year":"1998","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","article-title":"Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy","volume":"161","author":"Peffault de Latour","year":"2013","journal-title":"Br J Haematol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-60761-947-5_8","article-title":"Multiplex Ligation-dependent Probe Amplification (MLPA\u00ae) for the detection of copy number variation in genomic sequences","volume":"688","author":"Eijk-Van Os","year":"2011","journal-title":"Methods Mol Biol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"e2010033","DOI":"10.4084\/mjhid.2010.033","article-title":"Thrombotic microangiopathy in haematopoietic cell transplantation: an update","volume":"2","author":"Stavrou","year":"2010","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","article-title":"Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment","volume":"69","author":"Choi","year":"2009","journal-title":"Drugs"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705758","article-title":"Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?","volume":"40","author":"Batts","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1076029615599439","article-title":"Eculizumab in transplant-associated thrombotic microangiopathy","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1600-6143.2011.03841.x","article-title":"Thrombotic microangiopathy after living-donor liver transplantation","volume":"12","author":"Shindoh","year":"2012","journal-title":"Am J Transplant"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"e60352","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:10:43Z","timestamp":1695010243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201811000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000986","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}